Login
$HBIO
$8.91 -$0.48 (5.11%) Live

$HBIO 8-K SEC Filings

Filed On Filing
10 Nov 2026 8-K: Regulation FD Disclosure

NASDAQ: HBIO Harvard Bioscience Investor Overview November 202 6

10 Nov 2026 8-K: Results of Operations and Financial Condition

Harvard Bioscience Announces Third Quarter 2026 Financial Results

11 Aug 2026 8-K: Regulation FD Disclosure

NASDAQ: HBIO Harvard Bioscience Investor Overview August 202 6

11 Aug 2026 8-K: Results of Operations and Financial Condition

Harvard Bioscience Announces Second Quarter 2026 Financial Results

02 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

The purpose of the Harvard Bioscience, Inc. Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Harvard Bioscience, Inc. (the “Company”) and certain of its subsidiaries with opportunities to purchase shares of t...

12 May 2026 8-K: Regulation FD Disclosure

Forward - Looking Statements & Non - GAAP Financial Information Forward Looking Statements This document contains forward - looking statements within the meaning of the federal securities laws, including the Private Securities Litigation...

12 May 2026 8-K: Results of Operations and Financial Condition

Harvard Bioscience Announces First Quarter 2026 Financial Results

17 Mar 2026 8-K: Regulation FD Disclosure

NASDAQ: HBIO Harvard Bioscience Investor Overview March 202 6

12 Mar 2026 8-K: Results of Operations and Financial Condition

Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results

10 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation

This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made as of the 6th day of March, 2026 (the “Effective Date”), between Harvard Bioscience, Inc., a Delaware corporation (the “Company”), and Mark Frost (“Executive”...

06 Mar 2026 8-K: Submission of Matters to a Vote of Security Holders; Regulation FD Disclosure +1 more

Harvard Bioscience’s common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026

10 Feb 2026 8-K: Results of Operations and Financial Condition

Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas

29 Jan 2026 8-K: Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure

Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth

20 Jan 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

Article I, Section 5 of the Amended and Restated By-laws of Harvard Bioscience, Inc., is hereby deleted in its entirety and replaced with the following:

12 Jan 2026 8-K: Regulation FD Disclosure

HBio Confidential 1 NASDAQ: HBIO HBIO Investor Overview January 202 6

17 Dec 2025 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more

This LOAN AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of December 17, 2025 (the “Closing Date”) is entered into among Harvard Bioscience, Inc., a Delaware...

05 Dec 2025 8-K: Other Events

The Company is engaged in ongoing discussions relating to its existing credit agreement, dated December 22, 2020, as amended, with Citizens Bank, N.A., Wells Fargo Bank, N.A., and First-Citizens Bank & Trust Company (the “Credit Agreemen...

06 Nov 2025 8-K: Results of Operations and Financial Condition

Harvard Bioscience Announces Third Quarter 2025 Financial Results

03 Oct 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On October 2, 2025, Harvard Bioscience, Inc., (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had been...

09 Sep 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support